Liège, Belgium 5 July 2016 – Mithra Pharmaceuticals announces today that it obtained a new Marketing Authorisation for the commercialization of its product Tibelia® (bioequivalent of Livial® developed by Mithra) in Spain.
Share it
Latest news
Mithra announces updates to its 2024 financial calendar
28 March 2024
Mithra reports full year 2023 financial results
8 March 2024